Alcon has introduced its Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the U.S.

PanOptix Pro uses the company’s Enlighten NXT optical technology, which the company said delivers the highest reported light utilization of any trifocal IOL and the lowest light scatter. The enhancements also offer more uninterrupted light distribution from distance to near, as well as a 16% increase in optical image contrast between distance and intermediate.

The IOL will be the first presbyopia-correcting IOL available in the U.S. in Alcon’s single-use Clareon AutonoMe preloaded delivery system. It will also be available for use with the Clareon Monarch IV delivery system starting in 2026.

PanOptix Pro has powers ranging from from +6.0 through +30.0 diopters (in 0.5 diopter increments), +31.0 through +34.0 diopters (in 1.0 diopter increments), with a +2.17 diopter intermediate and a +3.25 diopter near add power. It will also be available with blue light and ultraviolet filtering.

It’s been introduced to select U.S. practices, with broad commercial rollout in May. Further markets will begin launch in late 2025.

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob Scott, VP, Intraocular Devices, R&D, Alcon. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”

Last week, the company earned CE mark approval for its Clarion Vivity intraocular lens (IOL).